Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation

Exclusion Criteria

• •Subject requires preoperative extracorporeal membrane oxygenation (ECMO)
• •Subject has second degree (Mobitz type I or II) or third-degree AV block or sinus node dysfunction
• •Subject has history of a bleeding diathesis
• •Subject has a history of clinically overt stroke within the past 3 years
• •Subject has a history of severe hypertension not adequately controlled with anti-hypertensive medications (Systolic blood pressure ≥ 200 mmHg and/or Diastolic blood pressure ≥ 110 mmHg)
• •Subjects who are receiving chronic anti-coagulation or anti-platelet therapy that would preclude surgery (prophylactic aspirin is acceptable)
• •Subjects with a history of metastatic cancer
• •Subjects with a history of seizure disorder
• •Subjects who are receiving or have received within 30 days any other investigational agents
• •Subjects who have received theophylline or aminophylline within 12 hours of study dosing